Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality

Feng Zhou(Wuhan University), Hongliang Li(Jiangnan University), Xiang Da(Wuhan University), Yufeng Yuan(Wuhan University), Bing-Hong Zhang(Union Hospital), Haofeng Lu(First People's Hospital of Jingzhou), Qingbo Xu(Southwest Medical University), Bin Wu(Union Hospital), Juan‐Juan Qin(Tianjin University of Finance and Economics), Jingjing Cai(Anhui Institute of Architectural Research and Design), Zhi‐Gang She(Wuhan University), Xinliang Ma(Thomas Jefferson University), Zhigang Lu(First People’s Hospital of Jingmen), Jing Xie(Wuhan University), Ye-Mao Liu(Wuhan University), Daihong Wang(Xianning Central Hospital), Haomiao Li(Wuhan University), Peter P. Liu(University of Ottawa), Peng Zhang(Shaoxing People's Hospital), Jun Yang(China Three Gorges University), Yibin Wang(Central South University), Jiahong Xia(Chinese Academy of Medical Sciences & Peking Union Medical College), Gang Peng(Suizhou Central Hospital), Xiaodong Huang(Zhejiang Chinese Medical University), Xigang Xia(Jingzhou Central Hospital), Xia Meng(Wuhan University), Xiaofeng Liao(Yale University), Chengzhang Yang(Wuhan University), Xiao-Jing Zhang(First Hospital of Shijiazhuang), Fang Lei(Wuhan University), Huilin Yang(Soochow University), Wei Xiang(Union Hospital)

Hypertension

June 4, 2020

Cited by 65

|New England Journal of Medicine|2022|2.5k

|Cell Metabolism|2020|1.7k

|European Journal of Heart Failure|2008|837

|Cell Metabolism|2023|777

|Virus Research|2020|637

Related Papers